Vanda Pharmaceuticals (VNDA) Scheduled to Post Quarterly Earnings on Wednesday

Posted by Latisha Jones on May 7th, 2024

Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) is set to release its earnings data after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of $0.05 per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) last issued its quarterly earnings data on Wednesday, February 7th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.05. Vanda Pharmaceuticals had a return on equity of 0.46% and a net margin of 1.30%. The company had revenue of $45.27 million during the quarter, compared to the consensus estimate of $37.00 million. On average, analysts expect Vanda Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Vanda Pharmaceuticals Price Performance

Shares of VNDA stock opened at $5.14 on Tuesday. Vanda Pharmaceuticals has a one year low of $3.30 and a one year high of $6.98. The business’s 50 day simple moving average is $4.32 and its 200 day simple moving average is $4.09. The stock has a market capitalization of $299.15 million, a PE ratio of 96.82 and a beta of 0.71.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on VNDA shares. StockNews.com cut shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, April 22nd. TheStreet downgraded shares of Vanda Pharmaceuticals from a “c-” rating to a “d” rating in a research report on Thursday, February 8th.

Check Out Our Latest Stock Analysis on Vanda Pharmaceuticals

Vanda Pharmaceuticals Company Profile

(Get Free Report)

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.